These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 25630217

  • 1. Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi.
    Becker LE, Weritz B, Yi X, Gross-Weissmann ML, Waldherr R, Zeier M, Sommerer C.
    Transpl Int; 2015 May; 28(5):553-64. PubMed ID: 25630217
    [Abstract] [Full Text] [Related]

  • 2. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF, Gonçalves RT, Leite M, Santos MA, Delgado AG, Cardoso LR, Takiya CM.
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [Abstract] [Full Text] [Related]

  • 3. Treatment with everolimus is associated with a procoagulant state.
    Baas MC, Gerdes VE, Ten Berge IJ, Heutinck KM, Florquin S, Meijers JC, Bemelman FJ.
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [Abstract] [Full Text] [Related]

  • 4. Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients.
    Alpay N, Ozkok A, Caliskan Y, Akagun T, Cinar SA, Deniz G, Sariyar M, Yildiz A.
    Clin Exp Nephrol; 2014 Dec; 18(6):961-7. PubMed ID: 24515306
    [Abstract] [Full Text] [Related]

  • 5. Effects of hypoxia-inducible factor-1alpha expression and C4d deposition in implantation biopsies on renal allograft.
    Kim DJ, Lee S, Kim SJ, Park SG, Kim JS, Hyun SJ, Song YS, Nam ES.
    Transplant Proc; 2008 Sep; 40(7):2145-6. PubMed ID: 18790175
    [Abstract] [Full Text] [Related]

  • 6. A comparative study on renal biopsy before and after long-term calcineurin inhibitors therapy: an insight for pathogenesis of its toxicity.
    Singh L, Singh G, Sharma A, Sinha A, Bagga A, Dinda AK.
    Hum Pathol; 2015 Jan; 46(1):34-9. PubMed ID: 25449629
    [Abstract] [Full Text] [Related]

  • 7. Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zeng J, Zhong Q, Feng X, Li L, Feng S, Fan Y, Song T, Huang Z, Wang X, Lin T.
    Front Immunol; 2021 Jan; 12():663602. PubMed ID: 34539621
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
    Cervera C, Cofan F, Hernandez C, Soy D, Marcos MA, Sanclemente G, Bodro M, Moreno A, Diekmann F, Campistol JM, Oppenheimer F.
    Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
    [Abstract] [Full Text] [Related]

  • 10. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Renal tubular acidosis in renal transplant patients: the effect of immunosuppressive drugs.
    Tanrisev M, Gungor O, Kocyigit I, Kurtulmus Y, Tugmen C, Colak H, Altunoren O, Kebapci E, Karaca C.
    Ann Transplant; 2015 Feb 09; 20():85-91. PubMed ID: 25659354
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Expression of transforming growth factor-beta1 and hypoxia-inducible factor-1alpha in renal transplantation.
    Lee S, Kim DJ, Park MG, Park SK, Kim JS, Hyun SJ, Oh JE, Nam ES, Joo SH.
    Transplant Proc; 2008 Sep 09; 40(7):2147-8. PubMed ID: 18790176
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients.
    Stallone G, Infante B, Schena A, Battaglia M, Ditonno P, Loverre A, Gesualdo L, Schena FP, Grandaliano G.
    J Am Soc Nephrol; 2005 Dec 09; 16(12):3755-62. PubMed ID: 16236802
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The prevalence of C4d-positive renal allografts in 134 consecutive biopsies in Thai patients.
    Cheunsuchon B, Vongwiwatana A, Premasathian N, Shayakul C, Parichatikanond P.
    Transplant Proc; 2009 Nov 09; 41(9):3697-700. PubMed ID: 19917370
    [Abstract] [Full Text] [Related]

  • 19. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
    Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ, ASCERTAIN Investigators.
    Transplantation; 2011 Aug 27; 92(4):410-8. PubMed ID: 21697773
    [Abstract] [Full Text] [Related]

  • 20. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.